A Case Report of Rare Presentation of Multiple Myeloma: A Case of Hepatic Amyloidosis

Main Article Content

Gautam M.
N. N. Anand
K. C. Kishore
Manoj Ravilla


It is uncommon for multiple myeloma (MM) to have liver involvement in a clinically documented occurrence. Approximately 15 % of MM patients have been observed to have amyloidosis, which is characterised as the clonal light-chain fibrils deposition in tissue. We documented a unique case of MM with a primary biliary system involvement and fulminant liver failure due to amyloidosis.Ascites, hepatosplenomegaly, anaemia, and hyperbilirubinemia were the patient's initial symptoms. , Thalidomide, dexamethasone , Bortezomib  were used in the conventional chemotherapy regimen, and this produced a striking response. Light chain amyloidosis-related liver damage may be the first blatant manifestation of MM. When patients exhibit vague symptoms and abnormal liver function tests, infiltrative illnesses including MM and amyloidosis should be taken into account. The prognosis of patients can be directly impacted by an accurate and prompt diagnosis. There is ongoing discussion over the best strategy for handling typical situations comparable to these.

Article Details

How to Cite
M., G. ., Anand, N. N. ., Kishore, K. C. ., & Ravilla, M. . (2023). A Case Report of Rare Presentation of Multiple Myeloma: A Case of Hepatic Amyloidosis. Journal of Coastal Life Medicine, 11(1), 195–200. Retrieved from https://www.jclmm.com/index.php/journal/article/view/308


Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. QJM. 2007;100:635–40. doi: 10.1093/qjmed/hcm077. [PubMed] [CrossRef] [Google Scholar]

Phekoo KJ, Schey SA, Richards MA, Bevan DH, Bell S, Gillett D, et al. population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol. 2004;127:299–304. doi: 10.1111/j.1365-2141.2004.05207.x. [PubMed] [CrossRef] [Google Scholar]

Kapadia SB. Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. Medicine (Baltimore) 1980;59:380–92. [PubMed] [Google Scholar]

Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50:29–40. [PubMed] [Google Scholar]

Perez-Soler R, Esteban R, Allende E, Tornos Salomo C, Julia A, Guardia J. Liver involvement in multiple myeloma. Am J Hematol. 1985;20:25–9. [PubMed] [Google Scholar]

Picken MM, Westermark P. Amyloid detection and typing: summary of current practice and recommendations of the consensus group. Amyloid. 2011;18:48–50. doi: 10.3109/13506129.2011.574354017. [PubMed] [CrossRef] [Google Scholar]

Schonland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 2012;119:488–93. doi: 10.1182/blood-2011-06-358507. [PubMed] [CrossRef] [Google Scholar]

Ales NC, Daniels JT, Frizell ER, Koff JM, Kaplan KJ, Wortmann GW. Multiple myeloma-associated amyloidosis manifesting as fulminant hepatic failure. South Med J. 2001;94:1036–8. [PubMed] [Google Scholar]

Yamamoto T, Maeda N, Kawasaki H. Hepatic failure in a case of multiple myeloma-associated amyloidosis (kappa-AL) J Gastroenterol. 1995;30:393–7. [PubMed] [Google Scholar]

Levy M, Fryd CH, Eliakim M. Intrahepatic obstructive jaundice due to amyloidosis of the liver. A case report and review of the literature. Gastroenterology. 1971;61:234–8. [PubMed] [Google Scholar]

Rahhal FE, Schade RR, Nayak A, Coleman TA. Hepatic failure caused by plasma cell infiltration in multiple myeloma. World J Gastroenterol. 2009;15:2038–40. doi: 10.3748/wjg.15.2038. [ PMC Free Article] [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc. 2010;85:232–8. doi: 10.4065/mcp.2009.0547. [ PMC Free Article] [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Vela-Ojeda J, Garcia-Ruiz Esparza MA, Padilla-Gonzalez Y, Sanchez-Cortes E, Garcia-Chavez J, Montiel-Cervantes L, et al. Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. Ann Hematol. 2009;88:59–66. doi: 10.1007/s00277-008-0554-0. [PubMed] [CrossRef] [Google Scholar]

Cross TJ, Wendon JA, Quaglia A, Salisbury JR, Heneghan MA, Harrison PM. Myeloma associated amyloidosis presenting as subacute liver failure. Postgrad Med J. 2006;82:e13. doi: 10.1136/pgmj.2006.044883. [ PMC Free Article] [PMC free article] [PubMed] [CrossRef] [Google Scholar]